nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.06.2013 | review

Biomolecular basis of the role of chronic psychological stress hormone ‘‘glucocorticoid’’ in alteration of cellular immunity during cancer

verfasst von: Md. Rubayet Ahsan, Abdullah Mahmud-Al-Rafat, Mahbub-E. Sobhani, Md. Abdul Wadud Molla

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Psychoneuroimmunology is the newly evolved science that describes the interaction between mind and body, mediated by reciprocal communications among the nervous, endocrine, and immune systems. This paper reviews the interrelationship between chronic psychological stress and cellular immunity during the progression of cancer. The immune system possesses the specialized defense mechanisms where an extensive network of immune cells exists through their cytokine milieu, which in turn can get highly affected by psychological stress. Under stressful conditions, the body increases the production of glucocorticoids via hypothalamic pituitary adrenal (HPA) axis. Glucocorticoids (GCs) suppress the cell mediated immunity (CMI) by reducing the production of cytokines and other effector molecules through the inhibition of transcription factors responsible for cytokine gene expression, mediated by glucocorticoid receptor. GCs inhibit the activities of natural killer (NK) cells, cytotoxic T lymphocytes (CTL), T helper (Th) cells, natural killer T (NKT) cells, macrophages and dendritic cells which play a vital role in tumor suppression. Th1 cytokines which activate the NK cell, CTL and macrophages are also inhibited by GCs. GCs are able to alter the appearance of macrophages and dendritic cells, providing pro-tumor activities, and also able to inhibit the antigen presentation which causes dysfunction of the adaptive immune response against tumor. GCs have been shown to reduce the expression of perforin, granzymes, tumor necrosis factor (TNF)- α, interferon (IFN)- γ, Fas, TNF receptor activation induced ligand (TRAIL), and other effector molecules which have direct effects in tumor destruction. Additionally, glucocorticoids induce tolerogenic dendritic cells and stimulate the T_reg cells to block the NK cell, CTL, NKT cell, and Th cell activity. Finally, it has been shown that chronic psychological stress exerts different immunomodulatory activities which facilitate the progression of cancer.

Vorheriger Artikel Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

Nächster Artikel Local therapy in prostate cancer—surgery versus radiation

Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol. 2002;71:9–15.PubMed

Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55:603–13.PubMedCrossRef

Refojo D, Liberman AC, Holsboer F, Arzt E. Transcription factor-mediated molecular mechanisms involved in the functional cross-talk between cytokines and glucocorticoids. Immunol Cell Biol. 2001;79:385–94.PubMedCrossRef

Zorilla EP, Luborsky L, McKay JR. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15(3):199–226.CrossRef

Kiecolt-Glaser JK, McGuire L, Robles TF, et al. Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. Annu Rev Psychol. 2002;53:83–107.PubMedCrossRef

Greenfeld K, Avraham R, Benish M, et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun. 2007;21(4):503–13.PubMedCrossRef

Saul AN, Oberyszyn TM, Daugherty C, et al. Chronic stress and susceptibility to skin cancer. J Natl Cancer Inst. 2005;97(23):1760–7.PubMedCrossRef

Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq C, Yamamoto KR. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc Natl Acad Sci U S A. 2004;101:15603–8.PubMedCrossRef

Adcock IM. Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther. 2001;14:211–9.PubMedCrossRef

10.

Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol. 2011;2011:676198.PubMedCrossRef

11.

Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–10.PubMedCrossRef

12.

Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature. 1986;319(6055):675–8.PubMedCrossRef

13.

Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Munz C. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 2004;172:1455–62.PubMed

14.

Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature. 2001;413(6852):165–71.PubMedCrossRef

15.

Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A. 2001;98(20):11521–6.PubMedCrossRef

16.

Zamai L, Ponti C, Mirandola P, et al. NK cells and cancer. J Immunol. 2007;178:4011–6.PubMed

17.

Kelly JM, Darcy PK, Markby JL, et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol. 2002;3(1):83–90.PubMedCrossRef

18.

Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol. Immunol. 2004;41:569–75.PubMedCrossRef

19.

Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Different checkpoints in human NK-cell activation. Trends Immunol. 2004;25:670–6.PubMedCrossRef

20.

Trinchieri G. Biology of natural killer cells. Adv. Immunol. 1989;47:187–376.PubMedCrossRef

21.

Sivori S, Carlomagno S, Moretta L,Moretta A. Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur. J. Immunol. 2006;36:961–7.PubMedCrossRef

22.

Moretta L, Ferlazzo G,Bottino C, Vitale M, Pende D, Zingari MC, Moretta A. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol. 2006;214:219–228.CrossRef

23.

Pende D, Bottino C, Castriconi R, et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol. Immunol. 2005;42:463–9.PubMedCrossRef

24.

Smyth MJ, Hayakawa Y, et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2:850–61.PubMedCrossRef

25.

Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–46.PubMedCrossRef

26.

Hamerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr Opin Immunol. 2005;17:29–35.PubMedCrossRef

27.

Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol. 2004;172:1333–9.PubMed

28.

Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends Immunol. 2004;25:47–52.PubMedCrossRef

29.

Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol. 2004;172:2048–58.PubMed

30.

Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358:502–11.PubMedCrossRef

31.

Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol. 2000;165:1847–53.PubMed

32.

Golab J. Interleukin 18-interferon inducing factor a novel player in tumor immunotherapy? Cytokine. 2000;12:332–8.PubMedCrossRef

33.

Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188:2375–80.PubMedCrossRef

34.

Mirandola P, Ponti C, Gobbi G, Sponzilli I, et al. Activated human NK and CD8 T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood. 2004;104:2418–24.PubMedCrossRef

35.

Sinkovics JG, Horvath JC. Human natural killer cells: a comprehensive review. Int J Oncol. 2005;27:5–47.PubMed

36.

Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4CD25 T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol. 2006;176:1582–7.PubMed

37.

Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon- stimulated genes as mediators of apoptosis. Apoptosis. 2003;8:237–49.PubMedCrossRef

38.

Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, Van Den Brink MR, Yagita H. Nature’s TRAIL on a path to cancer immunotherapy. Immunity. 2003;18:1–6.PubMedCrossRef

39.

Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007;220:129–50.PubMedCrossRef

40.

Steinman RM. Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat Med. 2007;13:1155–9.PubMedCrossRef

41.

Hashimoto SI, Suzuki T, Nagai S, Yamashita T, Toyoda N, Matsushima K. Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. Blood. 2000;96:2206–14.PubMed

42.

Sandel MH, Dadabayev AR, Menon AG, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res. 2005;11:2576–82.PubMedCrossRef

43.

Caux C, Vanbervliet B, Massacrier C, et al. Regulation of dendritic cell recruitment by chemokines. Transplantation. 2002;73:S7–11.PubMedCrossRef

44.

Clark GJ, Angel N, Kato M, Lopez J A, MacDonald K, Vuckovic S, Hart DN. The role of dendritic cells in the innate immune system. Microbes Infect. 2000;2:257–72.PubMedCrossRef

45.

Manna PP, Mohanakumar T. Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J Leukoc Biol. 2002;72:312–20.PubMed

46.

Huang J, Tatsumi T, Pizzoferrato E, Vujanovic N, Storkus WJ. Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Res. 2005;65:8461–70.PubMedCrossRef

47.

Nicolas A, Cathelin D, Larmonier N, Fraszczak J, Puig PE, Bouchot A, Bateman A, Solary E, Bonnotte B. Dendritic cells trigger tumor cell death by a nitric oxide dependent mechanism. J Immunol. 2007;179:812–8.PubMed

48.

Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007;13:4677–85.PubMedCrossRef

49.

Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med. 2003;197:1141–51.PubMedCrossRef

50.

Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ. Polarized type 1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1- type antimelanoma CD4 + T cell responses in vitro. J Immunother. 30:75–82, 2007.PubMedCrossRef

51.

Tourkova IL, Shurin GV, Chatta GS, Perez L, Finke J, Whiteside TL, Ferrone S, Shurin MR. Restoration by IL-15 of MHC class I antigen processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol. 2005;175:3045–52.PubMed

52.

Gerner MY, Casey KA, Mescher MF. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol. 2008;181:155–64.PubMed

53.

Shurin MR, Gabrilovich DI. Regulation of dendritic cell system by tumor. Cancer Res Ther Control. 2001;11:65–78.

54.

Lan YY, Wang Z, Raimondi G, Wu W, Colvin BL, de Creus A, Thomson AW. ‘‘Alternatively activated’’ dendritic cells preferentially secrete IL-10, expand Foxp3 +CD4 + T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol. 2006;177:5868–77.PubMed

55.

Shurin MR, Chatta G. Immunobiology of dendritic cells in cancer. In: Mechanisms of therapeutic reversal of immune suppression in cancer. Gabrilovich DI, Hurtwiz A (eds). 2008. pp. 101–30.

56.

Shurin GV, Yurkovetsky ZR, Shurin MR. Tumor-induced dendritic cell dysfunction. In: Ochoa AC, editor. Mechanisms of tumor escape from the immune response. New York: Taylor & Francis; 2003. pp. 112–38.

57.

Bellone G, Carbone A, Smirne C, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol. 2006;177:3448–60.PubMed

58.

Capobianco A, Rovere-Querini P, Rugarli C, Manfredi AA. Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells. Int J Cancer. 2006;119:2861–9.PubMedCrossRef

59.

Gratchev A, Kzhyshkowska J, Kannookadan S, Ochsenreiter M, et al. Activation of a TGF-β specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-β receptor II. J Immunol. 2008;180:6553–65.PubMed

60.

Sher A, Pearce E, Kaye P. Shaping the immune response to parasites: role of dendritic cells. Curr Opin Immunol. 2003;15:421–9.PubMedCrossRef

61.

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–86.PubMedCrossRef

62.

Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 2004;14:628–38.PubMedCrossRef

63.

Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol. 2011;89(4):pp. 557–63.PubMedCrossRef

64.

Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35.PubMedCrossRef

65.

Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953–64.PubMedCrossRef

66.

Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005;23:344–6.PubMedCrossRef

67.

Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451–83.PubMedCrossRef

68.

Verreck FA, de Boer T, Langenberg DM, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc Natl Acad Sci U S A. 2004;101:4560–5.PubMedCrossRef

69.

Fairweather D, Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J Autoimmun. 2009;33(3–4):222–30.PubMedCrossRef

70.

Sindrilaru A, Peters T, Wieschalka S, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest. 2011;121(3):985–97.PubMedCrossRef

71.

Hussein MR. Tumor-associated macrophages and melanoma tumorigenesis: integrating the complexity. Int J Exp Pathol. 2006;87:163–76.PubMedCrossRef

72.

Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451–83.PubMedCrossRef

73.

Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S. Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol. 2005;61:10–17.PubMedCrossRef

74.

Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86(5):1065–73.PubMedCrossRef

75.

Sica A, Schioppab T, Mantovania T, Allavenaa P. Tumor-associated macrophages are a distinct M2 polarized population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.PubMedCrossRef

76.

Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer. 2004;4:71–8.PubMedCrossRef

77.

Cruse JM, Lewis RE. The immune system victorious: selective preservation of self. Immunol Res. 1993;12(2):101–14.

78.

Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17(3):138–46.PubMedCrossRef

79.

Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science. 1996;272(5258):50–3.PubMedCrossRef

80.

Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251–76.PubMedCrossRef

81.

Elenkov IJ. Glucocorticoids and the Th1/Th2 Balance. Ann N Y Acad. Sci. 2004;1024:138–46.PubMedCrossRef

82.

Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer. 2004;4(1):71–8.PubMedCrossRef

83.

Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4 + T cells that facilitate tumor development. J Exp Med. 2007;204(5):1037–47.PubMedCrossRef

84.

DeNardo DG, Baretto JB, Andreu P, Vasquez L, Kolhatkar N, Tawfik D, et al. CD4 + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91–102.PubMedCrossRef

85.

Kimball JW. Cytotoxic T Lymphocytes (CTL), http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/C/CTL.html.

86.

Nagata S. Fas-mediated apoptosis. Adv Exp Med Biol. 1996;406:119–24.PubMedCrossRef

87.

Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what’s in a name? Nat Rev Immunol. 2004;4:231–7.PubMedCrossRef

88.

Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol. 2005;23:877–900.PubMedCrossRef

89.

Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of V14 NKT cells in innate and acquired immune response. Annu Rev Immunol. 2003;21:483–513.PubMedCrossRef

90.

Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest. 2004;114:1379–88.PubMed

91.

Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res. 2008;101:277–348.PubMedCrossRef

92.

Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med. 2002;196:119–27.PubMedCrossRef

93.

Kitamura HK, Iwakabe T, Yahata S, Nishimura A, Ohta Y, Ohmi M, Sato K, Takeda K. Okumura L, Van Kaer, et al. The natural killer T (NKT) cell ligand galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999;189:1121–8.PubMedCrossRef

94.

Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005;6:353.PubMedCrossRef

95.

Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16:115.PubMedCrossRef

96.

Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses. Int Immunol. 2009;21;1105–6.PubMedCrossRef

97.

Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804–11.PubMedCrossRef

98.

Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4( + ) CD25( + ) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766–72.PubMed

99.

Colombo MP, Piconese S. Regulatory T cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7:880–7.PubMedCrossRef

100.

Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272–6.PubMed

101.

Shevach EM. CD4 + CD25 + suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389–400.PubMed

102.

Sakaguchi S. Naturally arising CD4 + regulatory T cells for immunologic self tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62.PubMedCrossRef

103.

Krukowskia K, Eddya J, Kosika KL, Konleya T, Janusekb LW, Mathewsa HL. Glucocorticoid dysregulation of natural killer cell function through epigenetic modification. Brain Behav Immun. 2011;25(2):239–49.CrossRef

104.

Byrnes MD, Antoni MH, Goodkin K, et al. Stressful events, pessimism, natural killer cell cytotoxicity, and cytotoxic/suppressor T cells in HIV + black women at risk for cervical cancer. Psychosom Med. 1998;60:714–22.PubMed

105.

Irwin M, Daniels M, Risch C, et al. Plasma cortisol and natural killer cell activity during bereavement. Biol Psychiatry. 1988;24:173–78.PubMedCrossRef

106.

Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, et al. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol. 2005;23:7105–13.PubMedCrossRef

107.

Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol Bull. 2004;130:601–30.PubMedCrossRef

108.

Dragoş D, Tănăsescu MD. The effect of stress on the defense systems. J Med Life. 2010;3:10–18.PubMed

109.

Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000;20:6891–903.PubMedCrossRef

110.

Lim HY, Muller N, Herold MJ, et al. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology. 2007;122:47–53.PubMedCrossRef

111.

Schmidt M, Pauels HG, et al. Glucocorticoids induce apoptosis in human monocytes: potential role of IL-1β. J Immunol. 1999;163:3484–90.PubMed

112.

Tuckermann JP, Kleiman A, Moriggl R, Spanbroek R, Neumann A, Illing A, Clausen BE, et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest. 2007;117(5):1381–90.PubMedCrossRef

113.

Truckenmiller ME, Bonneau RH, Norbury CC. Stress presents a problem for dendritic cells: corticosterone and the fate of MHC class I antigen processing and presentation. Brain Behav Immun. 2006;20:210–18.PubMedCrossRef

114.

Moser M, De Smedt T, Sornasse T,Tielemans F, Chentoufi AA, Muraille E, Van Mechelen M, Urbain J, Leo O. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur. J. Immunol. 1995;25(10):2818–24.PubMedCrossRef

115.

Dhabhar FS, Satoskar AR, Bluethmann H, David JR, McEwen BS. Stress-induced enhancement of skin immune function: a role for gamma interferon. Proc Natl Acad Sci U S A. 2000;97:2846–51.PubMedCrossRef

116.

Elftman MD, Norbury CC, Bonneau RH, Truckenmiller ME. Corticosterone impairs dendritic cell maturation and function. Immunology. 2007;122:279–90.PubMedCrossRef

117.

Truckenmiller ME, Princiotta MF, Norbury CC, Bonneau RH. Corticosterone impairsMHCclass I antigen presentation by dendritic cells via reduction of peptide generation. J Neuroimmunol. 2005;160:48–60.PubMedCrossRef

118.

Matyszak MK, Citterio S, Rescigno M, Ricciardi-Castagnoli P. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur J Immunol. 2000;30(4):1233–42.PubMedCrossRef

119.

Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006;108(5):1435–40.PubMedCrossRef

120.

Chamorro v, Garcia-Vallejo JJ, Unger WWJ, et al. TLR Triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J Immunol. 2009;183(5):2984–94.PubMedCrossRef

121.

Ramirez F, Fowell DJ, Puklavec M, Simmonds S, Mason D. Glucocorticoids promote a TH2 cytokine response by CD4 + T cells in vitro. J Immunol. 1996;156(7):2406–12.PubMed

122.

Franchimont D, Galon J, Gadina M, et al. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol. 2000;164(4):1768–74.PubMed

123.

Saul AN et al. Chronic stress and susceptibility to skin cancer. J. Natl Cancer Inst. 2005;97:1760–7.PubMedCrossRef

124.

Hamdi H, Godot V, Maillot MC, et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood. 2007;110:211–9.PubMedCrossRef

125.

Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3( + )CD4( + )CD25( + ) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol. 2006;36:2139.PubMedCrossRef

126.

Chen CC, David AS, Nunnerley H, et al. Adverse life events and breast cancer: case-control study. BMJ. 1995;311:1527–30.PubMedCrossRef

127.

Duijts SF, Zeegers MP, Borne BV. The association between stressful life events and breast cancer risk: a metaanalysis. Int J Cancer. 2003;107:1023–29.PubMedCrossRef

128.

Geyer S. Life events prior to manifestation of breast cancer: a limited prospective study covering eight years before diagnosis. J Psychosom Res. 1991;35:355–63.PubMedCrossRef

129.

Lillberg K, Verkasalo PK, Kaprio J, et al. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol. 2003;157:415–23.PubMedCrossRef

130.

Giraldi T, Rodani MG, Cartei G, et al. Psychosocial factors and breast cancer: a 6-year Italian follow-up study. Psychother Psychosom. 1997;66:229–36.PubMedCrossRef

131.

Penninx BW, Guralnik JM, Pahor M, et al. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst. 1998;90:1888–93.PubMedCrossRef

132.

Price MA, Tennant CC, Smith RC, et al. The role of psychosocial factors in the development of breast carcinoma: Part I. The cancer prone personality. Cancer. 2001;91:679–85.PubMedCrossRef

Titel: Biomolecular basis of the role of chronic psychological stress hormone ‘‘glucocorticoid’’ in alteration of cellular immunity during cancer
verfasst von: Md. Rubayet Ahsan
Abdullah Mahmud-Al-Rafat
Mahbub-E. Sobhani
Md. Abdul Wadud Molla
Publikationsdatum: 01.06.2013
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-013-0075-y

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

CECOG experts’ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer

Single-agent bevacizumab as maintenance therapy in metastatic colorectal cancer: how long do we have to continue?

New developments in acute graft-versus-host disease

The role of maintenance therapy in metastatic colorectal cancer

Optimal surveillance strategy of localised testicular non-germ cell sex-cord stromal tumours

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody